Shares of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) were up 14.3% on Friday . The company traded as high as $15.92 and last traded at $15.31. Approximately 554,055 shares changed hands during trading, an increase of 390% from the average daily volume of 113,070 shares. The stock had previously closed at $13.40.

A number of analysts have recently weighed in on AQXP shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $28.00 price target on shares of Aquinox Pharmaceuticals in a report on Thursday, November 9th. Needham & Company LLC reissued a “buy” rating and issued a $25.00 price objective on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Canaccord Genuity reissued a “buy” rating and issued a $22.00 price objective on shares of Aquinox Pharmaceuticals in a research note on Tuesday, November 21st. Zacks Investment Research raised shares of Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research note on Tuesday, January 9th. Finally, BidaskClub raised shares of Aquinox Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, February 5th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $22.80.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.12. research analysts anticipate that Aquinox Pharmaceuticals Inc will post -2.08 earnings per share for the current year.

A number of large investors have recently modified their holdings of AQXP. University of Notre Dame DU Lac lifted its stake in Aquinox Pharmaceuticals by 11.1% in the 3rd quarter. University of Notre Dame DU Lac now owns 190,283 shares of the company’s stock valued at $2,700,000 after purchasing an additional 19,066 shares during the last quarter. Vanguard Group Inc. lifted its stake in Aquinox Pharmaceuticals by 6.6% in the 2nd quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock valued at $3,974,000 after purchasing an additional 17,455 shares during the last quarter. Citadel Advisors LLC bought a new position in Aquinox Pharmaceuticals in the 3rd quarter valued at approximately $194,000. Sphera Funds Management LTD. lifted its stake in Aquinox Pharmaceuticals by 21.7% in the 3rd quarter. Sphera Funds Management LTD. now owns 75,535 shares of the company’s stock valued at $1,072,000 after purchasing an additional 13,450 shares during the last quarter. Finally, Investment Centers of America Inc. bought a new position in shares of Aquinox Pharmaceuticals during the third quarter valued at $175,000. 96.26% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Aquinox Pharmaceuticals (AQXP) Trading Up 14.3%” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2018/02/11/aquinox-pharmaceuticals-aqxp-trading-up-14-3.html.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.